Results 41 to 50 of about 23,609 (230)
Cell Biology International, EarlyView.ABSTRACT Calreticulin is a multifunctional protein found in the endoplasmic reticulum lumen that is important for calcium homeostasis and glycoprotein folding. Mutations in exon 9 of the CALR gene are the second most common genetic cause of myeloproliferative neoplasms.
Mifra Faiz +2 more
wiley +1 more source
Archives of Disease in Childhood, 1980 Two siblings developed a fulminant fatal myeloproliferative disease at 7 and 8 weeks of age. The illness presented with pallor, haemorrhagic symptoms, and hepatosplenomegaly, and the blood picture was that of pancytopenia and leucoerythroblastosis. Bone marrow histology showed reduced haemopoiesis with generalised fibrosis.
C A, Sieff, P, Malleson
openaire +2 more sources
Therapeutic targeting of chromatin alterations in leukemia and solid tumors
International Journal of Cancer, EarlyView.Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner +7 more
wiley +1 more source
Journal of Orthopaedic Research, EarlyView.ABSTRACT Osteochondrosis/osteochondritis dissecans (OC/OCD) is a developmental orthopedic disease primarily affecting the knee, ankle, and elbow joints of children and multiple animal species. Subclinical lesions of OC/OCD have been described, but most can be visualized only histologically in cadaveric specimens.
Alexandra R. Armstrong +3 more
wiley +1 more source
Advances in the Management of Myelofibrosis [PDF]
Cancer Control, 2012 Myelofibrosis (MF) is a rare and serious hematologic malignancy classified as a Philadelphia chromosome-negative myeloproliferative neoplasm (MPN). The disease is more common in males and in older individuals. Of the MPNs, MF presents with the most severe morbidity and greatest mortality. Although the cause of MF is unknown, it is thought to occur from
Srdan Verstovsek +3 more
openaire +3 more sources
The odyssey of pacritinib in myelofibrosis
Blood Advances, 2022 Abstract Myelofibrosis (MF) can present with symptomatic splenomegaly and/or cytopenias including thrombocytopenia. Disease-related thrombocytopenia is a poor prognostic factor with a median overall survival of less than 2 years. Currently approved JAK1/2 inhibitors have not been evaluated in patients with platelets ≤ 50 × 109/L and in ...
Sangeetha Venugopal, John Mascarenhas
openaire +2 more sources
When, which and how to switch: Navigating JAK inhibitors in myelofibrosis
British Journal of Haematology, EarlyView.Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan +2 more
wiley +1 more source
British Journal of Haematology, EarlyView.This study demonstrates the clinical utility of a next‐generation sequencing (NGS)‐based chimerism assay (CASAL) in haematopoietic stem cell transplantation (HSCT). Compared to conventional short tandem repeat (STR) methods, CASAL showed significantly higher marker informativeness, detecting mixed chimerism (MC) below 5% recipient DNA with a median of ...
Jin Ju Kim +7 more
wiley +1 more source
Онкогематология, 2014 Literature data of idiopathic myelofibrosis are presented: classification, diagnostic criteria, morphological and molecular features. Particular attention is given to therapy of various clinical forms of primary myelofibrosis.
L. M. Meshcheryakova +4 more
doaj +3 more sources
Haematologica, 2012 Background The World Health Organization classification of myeloproliferative neoplasms discriminates between essential thrombocythemia and the prefibrotic phase of primary myelofibrosis.
Thomas Buhr +5 more
doaj +1 more source